Education
About Us
Working with TipRanks
Follow Us
Erasca (ERAS)
NASDAQ:ERAS
ERAS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.01 - $3.31
Previous CloseN/A
Volume148.24K
Average Volume (3M)787.40K
Market Cap
$445.36M
Enterprise Value$108.62M
Total Cash (Recent Filing)$300.66M
Total Debt (Recent Filing)$49.42M
Price to Earnings (P/E)―
Beta2.17
Next Earnings
Nov 05, 2025EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding283,670,140
10 Day Avg. Volume752,639
30 Day Avg. Volume787,401
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.24
Enterprise Value/Revenue25.89
Enterprise Value/Gross Profit222.13
Enterprise Value/Ebitda-0.75
Forecast
1Y Price Target
$5.00Price Target Upside218.47% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Clinical AdvancementsErasca advanced two key RAS-targeting programs into first-in-human studies, marking an important step for the company’s clinical pipeline.
Competitive PositioningErasca is developing both a pan-RAS and a pan-KRAS, positioning itself to be competitive in the RAS-driven tumor landscape.
Financial OutlookAs a result of this strategic realignment, Erasca has extended its projected cash runway into the second half of 2028.
Bears Say
Clinical Development ChallengesThe commercial opportunity for naporafenib is seen as underappreciated, suggesting potential for growth.
Clinical Efficacy ConcernsKey questions center on the translatability of the robust preclinical efficacy into human tumors with complex heterogeneity.
Risks And UncertaintiesThere are risks associated with the pre-IND asset, which could affect the company's future performance.
Erasca News
ERAS FAQ
What was Erasca’s price range in the past 12 months?
Erasca lowest stock price was $1.01 and its highest was $3.31 in the past 12 months.
What is Erasca’s market cap?
Erasca’s market cap is $445.36M.
When is Erasca’s upcoming earnings report date?
Erasca’s upcoming earnings report date is Nov 05, 2025 which is in 81 days.
How were Erasca’s earnings last quarter?
Erasca released its earnings results on Aug 12, 2025. The company reported -$0.12 earnings per share for the quarter, missing the consensus estimate of -$0.116 by -$0.004.
Is Erasca overvalued?
According to Wall Street analysts Erasca’s price is currently Undervalued.
Does Erasca pay dividends?
Erasca does not currently pay dividends.
What is Erasca’s EPS estimate?
Erasca’s EPS estimate is -0.11.
How many shares outstanding does Erasca have?
Erasca has 283,670,140 shares outstanding.
What happened to Erasca’s price movement after its last earnings report?
Erasca reported an EPS of -$0.12 in its last earnings report, missing expectations of -$0.116. Following the earnings report the stock price went up 3.846%.
Which hedge fund is a major shareholder of Erasca?
Currently, no hedge funds are holding shares in ERAS
Erasca Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.00 (218.47% Upside)
$5.00 (218.47% Upside)
Blogger Sentiment
Bullish
ERAS Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 42.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.7%
Last 30 Days ▼ 0.9%
Last 30 Days ▼ 0.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-39.38%
12-Months-Change
Fundamentals
Return on Equity
-31.16%
Trailing 12-Months
Asset Growth
-15.28%
Trailing 12-Months
Company Description
Erasca
Erasca, Inc. (ERAS) is a clinical-stage biopharmaceutical company focused on discovering and developing novel oncology therapies. The company aims to eradicate cancer by targeting biological drivers of the disease using precision medicine approaches. Erasca is working on a pipeline of small molecule drugs designed to inhibit oncogenic signaling pathways and address unmet needs in cancer treatment.
ERAS Stock 12 Month Forecast
Average Price Target
$5.00
▲(218.47% Upside)
Technical Analysis
Checkpoint Therapeutics
―
Eton Pharmaceuticals
―
Stoke Therapeutics
―
Oric Pharmaceuticals
―
Sana Biotechnology
―
Ownership Overview
22.58% Insiders
10.53% Mutual Funds
0.05% Other Institutional Investors
58.42% Public Companies and
Individual Investors